What is the common first-line therapy for most Schistosoma species infections?

Prepare for Success! In Clinical Laboratory Science with our Parasitology Test. Study with flashcards, multiple choice questions, hints, and explanations. Boost your readiness for the exam!

Multiple Choice

What is the common first-line therapy for most Schistosoma species infections?

Explanation:
Praziquantel is the go-to therapy for most Schistosoma infections because it effectively targets the adult worms of all major human schistosome species and is well tolerated, making it suitable for widespread use. It works by disrupting the parasite’s tegument and increasing calcium influx, causing paralysis and death of the worms, and it also reduces egg production, which helps lower pathology and transmission. While other anthelmintics like albendazole or mebendazole are used for nematodes and tapeworms, they do not reliably kill schistosomes, and ivermectin is mainly for nematode infections and certain parasites, not schistosomes. For these reasons, praziquantel is the first-line option across Schistosoma species, with some programs sometimes organizing a second dose to catch any remaining juveniles.

Praziquantel is the go-to therapy for most Schistosoma infections because it effectively targets the adult worms of all major human schistosome species and is well tolerated, making it suitable for widespread use. It works by disrupting the parasite’s tegument and increasing calcium influx, causing paralysis and death of the worms, and it also reduces egg production, which helps lower pathology and transmission. While other anthelmintics like albendazole or mebendazole are used for nematodes and tapeworms, they do not reliably kill schistosomes, and ivermectin is mainly for nematode infections and certain parasites, not schistosomes. For these reasons, praziquantel is the first-line option across Schistosoma species, with some programs sometimes organizing a second dose to catch any remaining juveniles.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy